|

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

RECRUITINGN/ASponsored by Coordinación de Investigación en Salud, Mexico
Actively Recruiting
PhaseN/A
SponsorCoordinación de Investigación en Salud, Mexico
Started2021-04-26
Est. completion2026-03-30
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05318274

Summary

An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of local tumor control, survival, acute and chronic toxicity. Shorter curse of radiation therapy may lead to similar local control of tumor cells and lower rates of toxicity than 3.1 standard treatment.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma.
* Treated with breast-conserving surgery and stage pT1-2 pN0 M0.
* Over 18 years.
* Patients who sign informed consent for research study.

Exclusion Criteria:

* Positive nodes.
* Clinical or pathological stage T3-T4.
* History of previous irradiation.
* Postoperative positive margin.

Conditions9

Breast CancerCancerDuctal Breast Carcinoma in SituEarly-stage Breast CancerInvasive Breast CancerStage 0 Breast CancerStage I Breast CancerStage IA Breast CancerStage IB Breast Cancer

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.